ArticleInfectious diseases and therapy2026
High-Dose Minocycline Improves Outcomes in Acinetobacter baumannii Group Pneumonia: A Propensity-Weighted Cohort Study with MIC-Based Insights for Breakpoint Revision.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionOptimal minocycline dosing for Acinetobacter baumannii group pneumonia remains unclear. We assessed the clinical impact of high-dose (HD) versus standard-dose (SD) minocycline and explored the predictive value of susceptibility breakpoints.
methodsIn this multicenter retrospective cohort study, hospitalized adults with AB group pneumonia treated with minocycline were classified into HD (200 mg IV q12h) or SD (100 mg IV q12h or 200 mg IV q24h) groups. Inverse probability of treatment weighting (IPTW) and multivariate logistic regression were applied to adjust for baseline differences. Kaplan-Meier survival and subgroup analyses were performed to evaluate dose-response effects and the utility of different minimum inhibitory concentration (MIC) breakpoints.
resultsAmong 106 patients (HD: 46; SD: 60), HD therapy was associated with significantly lower in-hospital mortality (28.6% vs. 48.3%; p = 0.046). HD minocycline remained a protective factor in multivariate and IPTW-adjusted models. Long-term (150-day) survival favored HD therapy (log-rank test, p = 0.028). In 28 patients infected with MIC-confirmed isolates, HD therapy consistently trended toward lower mortality across MIC strata. Notably, the pharmacokinetic/pharmacodynamic (PK/PD)-informed breakpoint (≤ 1 µg/ml) better discriminated survival benefit from HD therapy, whereas the Clinical and Laboratory Standards Institute (CLSI) 2024 breakpoint (≤ 4 µg/ml) did not. These findings support dose optimization and align with the revision of CLSI breakpoints in 2025, lowering the minocycline susceptibility breakpoint for Acinetobacter spp. to ≤ 1 µg/ml.
conclusionsHigh-dose minocycline significantly improved in-hospital survival for A. baumannii group pneumonia. PK/PD-informed breakpoint may offer greater clinical relevance for guiding minocycline therapy compared to CLSI 2024 breakpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.